DOCK4 and breast carcinoma: Although all four have published evidence linking them to breast cancer, we focused on DOCK4 for further investigation and clinical validation based on its published role in cell migration, including breast cancer cell migration, metastasis 18, 19, 20, 21 and tumour angiogenesis 14, processes known to be integral to dissemination of tumour cells and development of bone metastases.